Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer

PURPOSE: Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone. To build on this strategy and fully integrate a repetitively dosed bone-seeking...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Morris, Michael J., Pandit-Taskar, Neeta, Carrasquillo, Jorge, Divgi, Chaitanya R., Slovin, Susan, Kelly, William K., Rathkopf, Dana, Gignac, Gretchen A., Solit, David, Schwartz, Lawrence, Stephenson, Ryan D., Hong, Christina, Delacruz, Anthony, Curley, Tracy, Heller, Glenn, Jia, Xiaoyu, O'Donoghue, Joseph, Larson, Steven, Scher, Howard I.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2009
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684850/
https://ncbi.nlm.nih.gov/pubmed/19364960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.4164
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы